A carregar...
Off-target Lapatinib Activity Sensitizes Colon Cancer Cells through TRAIL Death Receptor Up-regulation
Lapatinib, a HER2/EGFR inhibitor, is a recently approved targeted therapy for metastatic breast cancer. As lapatinib enhances the efficacy of the antimetabolite capecitabine in breast cancer patients, we lapatinib also enhance the activity of anti-cancer agents in colorectal cancer. We found that la...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3769950/ https://ncbi.nlm.nih.gov/pubmed/21653830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3001384 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|